- Home
- VERO vs SNGX Comparison
VERO vs SNGX Comparison
Compare VERO & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERO
- SNGX
- Stock Information
- Founded
- VERO N/A
- SNGX 1987
- Country
- VERO Canada
- SNGX United States
- Employees
- VERO N/A
- SNGX N/A
- Industry
- VERO Medical/Dental Instruments
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- VERO Health Care
- SNGX Health Care
- Exchange
- VERO Nasdaq
- SNGX Nasdaq
- Market Cap
- VERO 4.5M
- SNGX 4.3M
- IPO Year
- VERO N/A
- SNGX 1987
- Fundamental
- Price
- VERO $2.40
- SNGX $3.70
- Analyst Decision
- VERO
- SNGX Strong Buy
- Analyst Count
- VERO 0
- SNGX 1
- Target Price
- VERO N/A
- SNGX $6.00
- AVG Volume (30 Days)
- VERO 31.4K
- SNGX 31.5M
- Earning Date
- VERO 08-14-2025
- SNGX 08-14-2025
- Dividend Yield
- VERO N/A
- SNGX N/A
- EPS Growth
- VERO N/A
- SNGX N/A
- EPS
- VERO N/A
- SNGX N/A
- Revenue
- VERO $60,107,000.00
- SNGX N/A
- Revenue This Year
- VERO N/A
- SNGX N/A
- Revenue Next Year
- VERO $7.47
- SNGX N/A
- P/E Ratio
- VERO N/A
- SNGX N/A
- Revenue Growth
- VERO N/A
- SNGX N/A
- 52 Week Low
- VERO $2.10
- SNGX $1.09
- 52 Week High
- VERO $14.50
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- VERO 45.57
- SNGX 60.84
- Support Level
- VERO $2.25
- SNGX $2.32
- Resistance Level
- VERO $2.49
- SNGX $6.23
- Average True Range (ATR)
- VERO 0.11
- SNGX 0.92
- MACD
- VERO -0.01
- SNGX 0.13
- Stochastic Oscillator
- VERO 31.98
- SNGX 44.64
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).